Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, octobre 02
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
BioNTech SE
BNTX
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$96.85
-1.45
-1.48%
Dern. MÀJ: Oct 2, 3:17 AM
$96.90
-1.40
-1.42%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
BioNTech Financials
BioNTech (BNTX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
BioNTech Lowers FY2026 Sales Guidance from $2.328B-$2.678B to $1.860B-$2.209B vs $2.500B Est
BioNTech (NASDAQ:BNTX) lowers FY2026 sales outlook from $2.328 billion-$2.678 billion to $1.860 billion-$2.209 billion vs $2.500 billion estimate.
Benzinga Newsdesk
PRO
BioNTech Q2 Adj. EPS $(2.58) Misses $(2.34) Estimate, Sales $122.766M Miss $182.020M Estimate
BioNTech (NASDAQ:BNTX) reported quarterly losses of $(2.58) per share which missed the analyst consensus estimate of $(2.34) by 10.26 percent. This is a 41.76 percent decrease over losses of $(1.82) per share from the
Benzinga Newsdesk
BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape
BioNTech shares fall after Q1 revenue miss and wider net loss, despite lower-than-expected loss and long-term cost-saving plans.
Vandana Singh
Earnings Scheduled For May 5, 2026
Benzinga Insights
PRO
BioNTech Affirms FY2026 Sales Guidance of $2.328B-$2.678B vs $2.560B Est
BioNTech (NASDAQ:BNTX) affirms FY2026 sales outlook from $2.328 billion-$2.678 billion to $2.328 billion-$2.678 billion vs $2.560 billion estimate.
Benzinga Newsdesk
PRO
BioNTech Q1 Adj. EPS $(2.28) Beats $(2.52) Estimate, Sales $138.000M Miss $214.620M Estimate
BioNTech (NASDAQ:BNTX) reported quarterly losses of $(2.28) per share which beat the analyst consensus estimate of $(2.52) by 9.52 percent. This is a 25.27 percent decrease over losses of $(1.82) per share from the same
Benzinga Newsdesk
